Long‐term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B


Long‐term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression. Therefore, current guidelines recommend the most potent drugs with optimal resistance profiles. Entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are the first‐line monotherapies for CHB. All of these drugs are highly effective in suppressing viral replication but with slightly different safety profiles. This review provides an overview of the long‐term efficacy and safety data that have become available over the 10 years since ETV and TDF were first approved for the treatment of chronic hepatitis, and recent data on TAF in patients with CHB.


chronic hepatitis B, efficacy, entecavir, safety, tenofovir alafenamide, tenofovir disoproxil fumarate, treatment


About Speaker

Maria BUTI

Professor of Medicine


City: Barcelona

Institution: Hospital Universitario Valle Hebron

Contact: 14100abf@comb.cat

Biography of Maria BUTI

Maria Butí earned her medical degree at the University of Barcelona and her PhD in Internal Medicine at the University “Autónoma” de Barcelona, Spain.
She is currently Professor of Medicine and Chief of Internal Medicine and Hepatology at the Hospital General Universitari Valle Hebron, Barcelona. Dr Butí has worked in viral hepatitis for the last 25 years, particularly in diagnosis and therapy of hepatitis B and C. She has been published widely in the field of liver disease, with numerous papers and contributions to books.

Dr Butí was the President of the Spanish Association for the Study of Liver Diseases. She is associate editor on Viral hepatitis in Journal of Hepatology and an active member of the EASL, and the AASLD and various professional societies.

View more